Motus GI Holdings Granted a U.S. Patent for a Key Feature Embodied by the Pure-Vu® System to Avoid Clogging in Cleansing the GI Tract

Rhea-AI Summary

Motus GI Holdings, Inc. announces the issuance of a new patent by the USPTO for their Colon Cleaning System with Automatic Self-Purging Feature, aimed at improving endoscopic outcomes. The patent covers the automated pressure management and self-purging feature of the Pure-Vu system, enhancing physician experience by avoiding procedure delays. This innovation addresses common issues in inpatient endoscopy, reducing the need for delayed, aborted, and repeat procedures, ultimately benefiting both patients and the healthcare system.

Positive

• Issuance of a new patent strengthens Motus GI Holdings, Inc.'s IP portfolio in the U.S.
• The patent covers the automated management of pressure for irrigation and self-purging feature of the Pure-Vu system.
• The self-purging feature includes sensors to detect blockages and automatically clear them without physician intervention.
• The innovation aims to improve inpatient endoscopy procedures by reducing delays and improving outcomes.
• Addressing issues like inadequate preparation and visualization in colonoscopies and upper GI bleed cases.
• The new patent application is a continuation of a previous U.S. patent application filed in 2019.

Negative

• None.

Insights

Medical Technology Analyst

The issuance of a new patent by the USPTO to Motus GI Holdings, Inc. for a 'Colon Cleaning System with Automatic Self-Purging Feature' represents a significant development in medical technology, particularly within the endoscopy field. The Pure-Vu system's enhancement is poised to address a common problem faced during inpatient endoscopies: the obstruction of the evacuation channel due to debris. By automating the management of pressure for irrigation and introducing a self-purging feature, the system aims to reduce procedure delays, which can be costly and inconvenient for both healthcare providers and patients.

From a financial perspective, the new patent could potentially reduce the number of delayed, aborted and repeat procedures, which currently place a considerable economic burden on the healthcare system. With up to 50% of inpatient colonoscopies resulting in an extra night of hospitalization due to inadequate preparation, the improved system could lead to significant cost savings and better allocation of hospital resources. Furthermore, the automated feature enhances the physician's experience, potentially increasing the adoption rate of the Pure-Vu system and positively impacting Motus GI's market share and revenue growth.

Healthcare Industry Analyst

From an industry perspective, the advancement of Motus GI's technology aligns with the broader trend of increasing automation in medical procedures to improve efficiency and outcomes. The self-purging feature of the Pure-Vu system could set a new standard for endoscopic procedures, potentially influencing competitor strategies and spurring innovation across the sector. Market research indicating that 30% of upper GI bleed cases suffer from inadequate visualization underscores the clinical need for improved endoscopic technology. By addressing this gap, Motus GI could strengthen its competitive position and contribute to the overall enhancement of patient care in gastroenterology.

Moreover, the fact that this patent is a continuation of previous applications suggests a strategic approach to intellectual property by Motus GI, aimed at building a robust patent portfolio. This approach not only protects the company's innovations but also creates barriers to entry for competitors, which could be beneficial for long-term market dominance and investor confidence.

Patent Law Expert

The grant of patent #11904085 to Motus GI Holdings, Inc. highlights the importance of intellectual property in the medical technology industry. Patents are crucial for protecting innovations and securing a competitive edge. The specific mention of 'systems and methods' in the patent indicates a broad scope of protection, covering various aspects of the technology and its application. This breadth can be advantageous in mitigating the risk of infringement by competitors and provides Motus GI with leverage in potential licensing deals or partnerships.

Furthermore, the continuation of previous patent applications demonstrates a methodical approach to expanding and strengthening the company's IP portfolio. This strategy not only fortifies the company's legal position but also enhances its valuation and attractiveness to investors, as a strong IP portfolio is often indicative of a company's commitment to innovation and its potential for market leadership.

FORT LAUDERDALE, Fla., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (“the “Company”) (NASDAQ: MOTS), a medical technology company focused on improving endoscopic outcomes and experiences, today announced that the United States Patent and Trademark Office (USPTO) has issued the Company a new patent (patent # 11904085) titled, “Colon Cleaning System with Automatic Self-Purging Feature.”

“We are pleased to announce further strengthening our IP portfolio in the U.S. This latest patent covers the automated management of pressure for irrigation and self-purging feature of the latest generation of the Pure-Vu system. This capability is key to enhancing the physician’s experience using the Pure-Vu, by avoiding procedure delays due to clogs,” commented Mark Pomeranz, Chief Executive Officer. “The Pure-Vu system’s self-purging feature embodies a series of sensors that can detect loss of suction and location of the potential blockage within the evacuation channel, automatically ceasing suction and reversing flow to purge the clogged material, thereby reopening the channel without requiring any action by the physician.”

The new patent covers systems and methods for cleaning a colon or other portion of the GI tract include optional use of sensors to detect conditions of blockage of flow of materials within an evacuation channel used to remove debris from the body; and devices and methods for purging such blockages from the evacuation channel. This latest patent application is a continuation of U.S. patent applications Ser. No. 16/389,955 filed on April 21, 2019.

Inpatient endoscopy on patients admitted to the hospital can be a difficult endeavor to get a quality procedure in a timely manner due to debris in the GI tract. This can lead to delayed, aborted and repeat procedures, which puts a burden on the healthcare system and the patient, both from a clinical and economic perspective. According to the literature, up to 50% of inpatient colonoscopies can have an extra night of hospitalization due to inadequate preparation and market research has shown that 30% of upper GI bleed cases have issues with adequate visualization effecting the length and outcome of the procedure.

About Motus GI Holdings, Inc.

Motus GI Holdings, Inc. is a medical technology company, with subsidiaries in the U.S. and Israel, providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions.

For more information, visit www.motusgi.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms, including without limitation, statements relating to the Company’s current views and assumptions with respect to future events regarding its business, the success of the Company’s current and future business strategies, competitive position, and other statements that are predictive in nature, risks related to market and other conditions, risks inherent in the development and commercialization of potential products, possible or assumed future results of operations, potential growth opportunities, uncertainty in the timing and results of clinical trials or regulatory approvals, maintenance of intellectual property rights or other risks discussed in the Company’s quarterly and annual reports filed with the SEC, and its other filings with the SEC. Undue reliance should not be placed on any such forward-looking statements as actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

Investor Contact:
Troy Williams
LifeSci Advisors
(518) 221-0106
twilliams@lifesciadvisors.com 

FAQ

What is the title of the new patent issued to Motus GI Holdings, Inc.?

The new patent issued to Motus GI Holdings, Inc. is titled 'Colon Cleaning System with Automatic Self-Purging Feature'.

What does the new patent cover?

The new patent covers the automated management of pressure for irrigation and the self-purging feature of the latest generation of the Pure-Vu system.

How does the self-purging feature of the Pure-Vu system benefit physicians?

The self-purging feature of the Pure-Vu system includes sensors that can detect blockages and automatically clear them without requiring any action by the physician, thus enhancing the physician's experience and avoiding procedure delays.

What common issues in inpatient endoscopy does the new patent aim to address?

The new patent aims to address common issues in inpatient endoscopy, such as delayed, aborted, and repeat procedures, due to debris in the GI tract, ultimately benefiting both patients and the healthcare system.

What percentage of inpatient colonoscopies may have an extra night of hospitalization due to inadequate preparation?

Up to 50% of inpatient colonoscopies may have an extra night of hospitalization due to inadequate preparation, according to the literature.

How does the new patent innovation impact the length and outcome of upper GI bleed cases?

Market research has shown that 30% of upper GI bleed cases have issues with adequate visualization, affecting the length and outcome of the procedure, which the new patent innovation aims to address.